( Tischler et al . 2017 ). Activation of TERT as a result of promoter mutations (specifically, chr5:1295228C > T and chr5:1295250C > T) were initially found in melanoma ( Horn et al . 2013 ) and have subsequently been shown to be one of the most
Search Results
Trisha Dwight, Aidan Flynn, Kaushalya Amarasinghe, Diana E Benn, Richard Lupat, Jason Li, Daniel L Cameron, Annette Hogg, Shiva Balachander, Ida L M Candiloro, Stephen Q Wong, Bruce G Robinson, Anthony T Papenfuss, Anthony J Gill, Alexander Dobrovic, Rodney J Hicks, Roderick J Clifton-Bligh, and Richard W Tothill
Johan O Paulsson, Ninni Mu, Ivan Shabo, Na Wang, Jan Zedenius, Catharina Larsson, and C Christofer Juhlin
Introduction The telomerase enzyme consists of a protein component with reverse transcriptase activity, encoded by the telomerase reverse transcriptase ( TERT ) gene ( Cong et al. 2002 ). Telomerase activation is a hallmark of malignant
Tiantian Liu, Taylor C Brown, C Christofer Juhlin, Adam Andreasson, Na Wang, Martin Bäckdahl, James M Healy, Manju L Prasad, Reju Korah, Tobias Carling, Dawei Xu, and Catharina Larsson
telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase enzyme complex. As the de-repression of TERT gene transcription is intimately coupled with the acquisition of telomerase activity in transformed cells, regulatory mechanisms
Matthias S Dettmer, Anja Schmitt, Hans Steinert, David Capper, Holger Moch, Paul Komminoth, and Aurel Perren
transcriptase ( TERT ) gene, which encodes for the catalytic subunit of telomerase, is implicated in tumorigenesis and cell immortalization. The two promoter mutations C228T and C250T were recently reported in human melanomas and other human cancer types
Rengyun Liu and Mingzhao Xing
Introduction Telomerase reverse transcriptase in human cancer Telomerase reverse transcriptase (TERT) is the catalytic protein subunit of telomerase, which, together with an integral RNA subunit and several species-specific assessor proteins
Soomin Ahn, Tae Hyuk Kim, Sun Wook Kim, Chang Seok Ki, Hye Won Jang, Jee Soo Kim, Jung Han Kim, Jun-Ho Choe, Jung Hee Shin, Soo Yeon Hahn, Young Lyun Oh, and Jae Hoon Chung
frequency of PD-L1 expression in various thyroid cancers and the relationship between PD-L1 expression and clinicopathologic factors including BRAF , TERT promoter status and disease progression were evaluated. Materials and methods Case
Young Shin Song, Seong-Keun Yoo, Hwan Hee Kim, Gyeongseo Jung, Ah-Reum Oh, Ji-Young Cha, Su-jin Kim, Sun Wook Cho, Kyu Eun Lee, Jeong-Sun Seo, and Young Joo Park
Introduction Telomerase reverse transcriptase ( TERT ) has a canonical role maintaining telomere length and the nontelomeric function, which can regulate the expression of various genes involved in cell proliferation and cellular signaling
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, and Mingzhao Xing
telomerase reverse transcriptase (TERT). Promoter mutations in the TERT gene on chromosome 5 have recently been reported in melanomas ( Horn et al . 2013 , Huang et al . 2013 ). Two TERT promoter mutations, 1 295 228 C>T and 1 295 250 C>T (termed C228T
Rengyun Liu and Mingzhao Xing
required to achieve this. Two recently discovered mutations in the promoter of the gene for telomerase reverse transcriptase (TERT) in thyroid cancer show promise in this regard – chr5:1 295 228C>T and chr5:1 295 250C>T (termed herein as C228T and C250T
Ebtesam Qasem, Avaniyapuram Kannan Murugan, Hindi Al-Hindi, Mingzhao Xing, Mai Almohanna, Meshael Alswailem, and Ali S Alzahrani
reverse transcriptase ( TERT) promoter ( Landa et al . 2013 , Liu et al . 2013 , 2014 a , Vinagre et al . 2013 , Liu & Xing 2014 , Melo et al . 2014 , Ngeow & Eng 2014 , Wang et al . 2014 a , Xing et al . 2014 , Gandolfi et al . 2015
